Market Flash on RGC
Equilend Data & Analytics identifies Regencell Bioscience as a prime short squeeze candidate, with its short squeeze score at 88. With utilization approaching 86% and extremely elevated borrow fees of 60,000 BPS, short sellers are facing mounting pressure. This $1.2B biotech powerhouse has seen its short squeeze score surge from 21 to 88 in just one week, potentially triggering a significant short covering rally.
Company Overview
Regencell Bioscience Holdings Ltd. is a biopharmaceutical company focused on the research, development and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders including ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder). Founded in Hong Kong and now headquartered in the United States, the company combines traditional healing methodologies with modern scientific validation to create standardized treatment protocols. Regencell’s approach centers on personalized formulations of natural herbs and compounds, tailored to individual patient profiles.
Note: Data as of May 6, 2025. Equilend Short Squeeze Score ranges from 0-100, with higher scores indicating greater likelihood of a short squeeze.
The stock’s utilization rate of 86% is approaching critical levels, suggesting that available shares for borrowing are becoming scarce. This high utilization is accompanied by an extraordinary borrowing fee of 60,000 BPS (600% annualized). These securities lending metrics indicate supply constraints and significant costs for maintaining short positions.
Contact us at https://equilend.com/services/equilend-short-squeeze-score/ to find out how you can leverage Equilend’s Short Squeeze Score today.
Bloomberg Terminal users can subscribe to Equilend’s exclusive Orbisa securities lending data by entering terminal shortcut APPS ORBISA
